Copyright
©The Author(s) 2015.
World J Clin Pediatr. Nov 8, 2015; 4(4): 94-105
Published online Nov 8, 2015. doi: 10.5409/wjcp.v4.i4.94
Published online Nov 8, 2015. doi: 10.5409/wjcp.v4.i4.94
Table 1 Intergroup rhabdomyosarcoma study pretreatment staging and clinical grouping classification
| Stage | Sites | T1 | Size2 | N3 | M4 |
| 1 | Orbit, head and neck (excluding parameningeal), genitourinary tract (non-bladder, non-prostate), biliary tract | T1 or T2 | a or b | N0 or N1 or Nx | M0 |
| 2 | Bladder.Prostate, extremity, parameningeal, others (trunk, retroperitoneum, etc.) | T1 or T2 | a | N0 or Nx | M0 |
| 3 | Bladder.Prostate, extremity, parameningeal, others (trunk, retroperitoneum, etc.) | T1 or T2 | a | N1 | M0 |
| b | N0 or N1 or Nx | M0 | |||
| 4 | Any sites | T1 or T2 | a or b | N0 or N1 | M1 |
| Clinical group | Description | ||||
| I | Localized disease, completely resected | ||||
| II | Grossly resected tumor with evidence of regional spread | ||||
| IIA: Grossly resected tumor with microscopic residual disease | |||||
| IIB: Involved regional nodes completely resected with no microscopic residual disease | |||||
| IIC: Involved regional nodes grossly resected with evidence of microscopic residual disease | |||||
| III | Incomplete resection with gross residual disease after biopsy or after gross or major resection of the primary tumor | ||||
| IV | Distant metastatic disease present at diagnosis | ||||
Table 2 Risk group stratification for rhabdomyosarcoma according to the International Rhabdomyosarcoma Study
| Risk group | Histology | Pretreatment stage | Clinical group |
| Low (subset 1) | Embryonal | 1 | I, II |
| 1 | III (orbit) | ||
| 2 | I, II | ||
| Low (subset 2) | 1 | III (non-orbit) | |
| 3 | I, II | ||
| Intermediate | Embryonal | 2, 3 | III |
| Alveolar | 1, 2, 3 | I, II, III | |
| High | Any | 4 | IV |
Table 3 Risk stratification in nonrhabdomyosarcoma soft tissue sarcoma and treatment proposal according to the Children's Oncology Group (NCT00346164)
| Risk group | Factors | Proposed treatment | |||
| Grade | Size | Stage | Initial resectability | ||
| Low | Low | Any | Nonmetastatic | Gross resection | Observation |
| High | < 5 cm | Nonmetastatic | Without microscopic margins | Observation | |
| High | < 5 cm | Nonmetastatic | With microscopic margin | Adjuvant radiation therapy | |
| Intermediate | High | > 5 cm | Nonmetastatic | Gross resection | Adjuvant chemotherapy and radiation therapy |
| High | > 5 cm | Nonmetastatic | Unresected | Neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy with or without radiation therapy | |
| High | Low | Any | Metastatic | Gross resection | Observation |
| High | Any | Metastatic | Gross resection | Adjuvant chemotherapy and radiation therapy | |
| High | Any | Metastatic | Unresected | Neoadjuvant chemoradiotherapy, surgery, adjuvant chemotherapy with or without radiation therapy | |
- Citation: Sangkhathat S. Current management of pediatric soft tissue sarcomas. World J Clin Pediatr 2015; 4(4): 94-105
- URL: https://www.wjgnet.com/2219-2808/full/v4/i4/94.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v4.i4.94
